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Abstract
Background: KRAS mutations represent key alterations in colorectal cancer development and
lead to constitutive EGFR signaling. Since EGFR inhibition represents a therapeutic strategy in
advanced colorectal cancer, KRAS mutation analysis has quickly been introduced as a treatment-
predictive test.
Methods: We used a real-time PCR based method to determine KRAS mutations in 136 colorectal
cancers with mutations identified in 53 (39%) tumors.
Results: KRAS mutations were significantly more often found in rectal cancer (21/38, 55%) than in
colon cancer (32/98, 33%) (P = 0.02). This finding was explained by marked differences mutation
rates in female patients who showed mutations in 33% of the colon cancers and in 67% of the rectal
cancers (P = 0.01). Concurrent KRAS mutations were identified in three tumors; two colorectal
cancers harbored Gly12Asp/Gly13Asp and Gly12Cys/Gly13Asp and a third tumor carried
Gly12Cys/Gly12Asp in an adenomatous component and additionally acquired Gly12Val in the
invasive component.
Conclusion: The demonstration of a particularly high KRAS mutation frequency among female
rectal cancer patients suggests that this subset is the least likely to respond to anti-EGFR therapies,
whereas the observation of concurrent KRAS mutations imply that repeated KRAS targeting may
occur during tumor progression in a subset of colorectal cancers.
Background
Inhibition of the epidermal growth factor receptor (EGFR)
signaling pathway represents a therapeutic option in
advanced colorectal cancer. Improved response rates and
prolonged time to metastasis/survival has been demon-
strated with the currently registered EGFR blocking anti-
bodies cetuximab and panitumumab, and additional
EGFR inhibitors are in various stages of clinical trials.
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Mutations in the KRAS oncogene typically occur already
in the late adenoma stage and have since long been recog-
nized as a key event in colorectal cancer development [1].
Overall, KRAS mutations are found in about 40% of the
tumors and are predominantly located in codons 12 (82%
of the mutations reported) and 13 (17%) http://
www.sanger.ac.uk/genetics/CGP/cosmic. Activating
mutations lead to permanently GTP bound KRAS and
constitutive downstream pathway signaling, also in the
absence of upstream EGFR stimulation. Presence of KRAS
mutations therefore represents a negative predictor of
response to EGFR therapy and KRAS mutation testing has
rapidly moved into the molecular diagnostic work-up of
colorectal cancers considered for EGFR treatment [2,3].
Quality assurance programs for KRAS mutation testing
and practice guidelines related to e.g. optimal testing
material, methodological considerations and recommen-
dations for the reporting of the results are currently being
developed [4]. PCR-based assays constitute the corner-
stone for clinical KRAS testing since these analyses allow
high-throughput testing and have a favorable sensitivity,
also in samples with low tumor cell content. We report the
experiences from our first 136 treatment-predictive KRAS
tests and herein report significant differences in mutation
frequencies in colon cancer and rectal cancer and coexist-
ing KRAS mutations in a subset of the tumors.
Methods
KRAS mutation testing was performed in 136 adenocarci-
nomas of the colon (n = 98) and the rectum (n = 38). The
mean age was 56 (21-81) years and the series included 64
(47%) females. Representative tumor blocks were selected
and were in the majority of the cases derived from the pri-
mary tumor, in 13 cases from metastatic tissue and in four
cases from a local recurrence. Presence of at least 20%
tumor cells in the tissue was verified by a pathologist.
DNA was extracted from serial sections of formalin-fixed,
paraffin-embedded tumor tissue using the Qiamp DNA
FFPE tissue Kit (Qiagen, Hilsen, Germany) according to
the manufacturer's recommendations. Standard clinical
analysis applied the DxS real-time PCR based kit (Roche
Diagnostics, Basel, Switzerland), which identifies 7 differ-
ent KRAS mutations in exons 12 and 13 with high sensi-
tivity. In order to confirm presence of double or triple
coexisting mutations, samples with such unusual patterns
were also subjected to pyrosequencing (PyroMark™ Q96
KRAS v2.0, Qiagen, Hilsen, Germany) according to the
manufacturer's recommendations on PSQ™HS96A [5].
Mutations were quantified using the machine's software.
Statistical analysis used a Chi2 test and the level of signif-
icance was set at 5%. KRAS mutation testing was carried
out as part of standard care, all patients provided
informed consent for testing, and the study was con-
ducted according to the Helsinki declaration.
Results
KRAS mutations were identified in 53/136 (39%) colorec-
tal cancers. Overall, mutation status did not correlate with
sex when analyzed in the whole cohort with mutations in
28/64 (44%) women and in 5/72 (35%) men (P = 0.28)
or age (mean age 55 years in the mutant group and 57
years in the wild-type group). KRAS mutations, however,
significantly correlated with tumor location with muta-
tions found in 32/98 (33%) colon cancers and 21/38
(55%) rectal cancers (P = 0.02; Chi2-test). This difference
was related to a high mutation rate in female rectal cancer
patients (14/21, 67%) compared to females with colon
cancer (14/43, 33%) (p = 0.01), whereas no significant
difference related to tumor location was identified in men
(41% in rectal cancer and 33% in colon cancer, P = 0.52).
Though the materials in subsets are small, women with
KRAS mutant rectal cancers were diagnosed mean 10 years
earlier (mean age 48, range 25-71, years) than those with
KRAS wild-type rectal cancers (mean age 58, range 52-70,
years).
The mutation spectrum revealed the expected codon 12
and 13 mutations with the p.Gly12Asp, p.Gly13Asp, and
p.Gly12Val being the most commonly found (table 1) [6].
Three tumors showed two-three different KRAS mutations
(figure 1), which were identified using real-time PCR and
verified in a separate tumor block and using pyrosequenc-
ing as a complementary method. The first case was a colon
cancer from a 65-year old man with hereditary nonpoly-
posis colorectal cancer and a germline mutation in the
MLH1 gene. The tumor was found to harbor two KRAS
mutations, Gly12Asp (ΔCT value 6.9, cutoff 8) and
Gly13Asp (ΔCT value 5.6, cutoff 9). The patient had 10
years earlier developed two synchronous colon cancers,
both of which were retrospectively analyzed, but neither
of these contained any KRAS mutation (data not shown).
The second case was a 68-year old man with a rectal cancer
metastatic to the liver. The primary tumor revealed coex-
isting coexistence of the KRAS mutations Gly12Cys (ΔCT
value 5.4, cutoff 7.0) and Gly13Asp (ΔCT 4.8, cutoff 9.0).
The third case was a 47-year old woman who presented
with a rectal cancer and concurrent liver metastases. The
initial biopsy from the rectal tumor revealed only adeno-
matous components, whereas a second biopsy contained
infiltrative adenocarcinoma. Unfortunately, no histologic
sample from the liver lesions was available. The tubulovil-
lous adenoma harbored the mutations Gly12Asp (ΔCT
value 6.2, cutoff 8.0) and Gly12Cys (ΔCT value 3.9, cutoff
7.0), whereas the sample with also an invasive compo-
nent contained both these mutations and in addition
(contained) a Gly12Val mutation (ΔCT value 4.1, cutoff
6.5). All mutations were identified by real-time PCR and
verified using pyrosequencing.BMC Clinical Pathology 2009, 9:8 http://www.biomedcentral.com/1472-6890/9/8
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Discussion
The overall KRAS mutation frequency of 39% is in line
with the results from previous studies http://
www.sanger.ac.uk/genetics/CGP/cosmic, though the dif-
ferent mutation rates - 33% in colon cancer and 55% in
rectal cancer (p = 0.02) - has not been reported in con-
junction with treatment-predictive testing. Distinct
molecular pathways are preferentially involved in the ade-
noma-carcinoma sequence in the proximal and the distal
colon with TP53 and KRAS mutations being favored in
rectal cancer, whereas mismatch repair defects are more
common in proximal colon tumors [7]. A higher muta-
tion frequency in rectal cancers compared to colon cancer
has previously been described, although the magnitude
has been lower than identified herein [8]. The effect seems
to be limited to females with rectal cancer, 67% of whom
harbored KRAS mutations. This observation is in line with
the findings in a large population-based series from the
Netherlands in which Brink et al. reported a higher KRAS
mutation rate in female rectal cancer patients [8]. Further-
more, in the subset of females with rectal cancer the KRAS
mutant tumors were diagnosed mean 10 years earlier
(mean age 48 years) behaviour than the wild-type tumors
(mean age 58). Though this observation is new and needs
Real-time PCR analysis identified coexisting KRAS mutations in three cases Figure 1
Real-time PCR analysis identified coexisting KRAS mutations in three cases. Case 1) colon cancer with the 
Gly12Asp and Gly13Asp mutations, Case 2) colon cancer with coexisting Gly12Cys and Gly13Asp mutations, and Case 3) a 
rectal tumor that revealed Gly12Asp and Gly12Cys in adenomatous components and an additional Gly12Val mutation in the 
invasive tumor component. All mutations were verified using pyrosequencing. Case 1 contained 12% Gly12Asp and 24% 
Gly13Asp, and case 2 4% Gly12Cys and 34% Gly13Asp. Case 3 harboured 17% Gly12Asp and 22% Gly12Cys in the adenoma-
tous component, and 10% Gly12Asp, 7% Gly12Cys, and 12% Gly12Val in the invasive component (data not shown).
Table 1: Summary of KRAS mutations identified.
KRAS mutation Amino acid change *Number (%) mutations Distribution colon/rectum
c.35G>A p.Gly12 Asp 19 (33) 13/6
c.38G>A p.Gly13Asp 12 (21) 8/5
c.35G>T p.Gly12Val 10 (18) 4/6
c.34G>T p.Gly12Cys 7 (12) 6/1
c.34G>A p.Gly12Ser 5 (9) 1/4
c.35G>C p.Gly12Ala 4 (7) 3/1
c.34G>C p.Gly12Arg - -
*Represents 53 tumors, including 3 with coexisting mutationsBMC Clinical Pathology 2009, 9:8 http://www.biomedcentral.com/1472-6890/9/8
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confirmation, a recent study has demonstrated that early-
onset colorectal cancers frequently show pathologic fea-
tures associated with aggressive clinical features [9]. The
tumors here investigated were selected based on potential
EGFR treatment, which may bias the results toward
tumors prone to metastatic development, though the
overall KRAS mutation frequency of 39% and the relation
between colon cancer and rectal cancer are as expected.
The differences in KRAS mutation rates identified suggest
that sex and tumor location influence the chance of clini-
cal usefulness of EGFR inhibitors with a particularly low
likelihood of benefit among female rectal cancer patients.
A stepwise accumulation of mutations in different path-
ways constitutes a hallmark of colorectal cancer develop-
ment. The observation of coexisting KRAS mutations in a
small number of colorectal cancers, however, suggests that
some tumors benefit from repeated targeting of the same
pathway. This observation is in line with the association
between KRAS mutations and 12p gain in colorectal ade-
nomas [10]. Recently, the "two-hit-hypothesis" was chal-
lenged in a study of inactivating APC gene mutations in
colorectal cancer, in which three hits - including muta-
tions, deletions, and copy number gain - were demon-
strated in a subset of the tumors [11]. APC  gene
mutations, as well as KRAS mutations, are recognized as
early events in colorectal cancer development. Based on
our results and previous observations, concurrent KRAS
mutations seem to occur in about 3% of colorectal can-
cers. The majority of these cases show coexisting muta-
tions in codon 12, whereas a smaller number have
mutations in different codons (12 and 13 or 12 and
another codon) [8,12-15]. Different KRAS mutations have
shown variable efficacy in downstream signaling trans-
duction and also seem to involve different effector mole-
cules [16,17]. The specific KRAS mutation may thereby
influence different aspects of tumor progression, which
could explain why repeated KRAS targeting is observed in
a subset of colorectal cancer. Interestingly the p.Gly12Val
mutation was found in 10 rectal cancers and 4 colon can-
cers, suggesting an overrepresentation in the former
tumor type. This mutation has also been linked to a worse
prognosis [16]. The addition of a p.Gly12Val mutation in
the invasive component of a tumor already containing
dual KRAS mutations (figure 1, case 3) suggests a role for
repeated KRAS targeting during tumor progression and
serves as a reminder to consider coexisting mutations
when unexpected patterns occur in treatment predictive
testing.
Conclusion
In conclusion, our experience from predictive testing for
KRAS mutations reveal a high mutation frequency (67%)
in rectal cancers from females and thus implicates that
this subset is the least likely to respond to anti-EGFR ther-
apies. Concurrent KRAS mutations were observed in 3/
136 tumors and although it remains a rare finding sug-
gests that repeated KRAS  targeting may occur during
colorectal cancer progression.
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